arrow
P

Pedro L. Fernández

Universitat de Girona
H指数:55
被引数:9,733

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Segmenting Invasive and In Situ Carcinoma in Breast WSIs with a Pretrained Histopathology Transformer

使用预训练的病理学转换器分割乳腺癌WSI中的浸润性和原位癌

2026-01-010
PRE
Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer

免疫相关转录组特征可预测HR+/HER2–乳腺癌中CDK4/6抑制剂的疗效

2025-08-070
OA
Towards a multicentric open DigitAL PatHology assIstant beNchmark: Initial Results from the DALPHIN Study
2025-03-010
PRE
Standardization through education of molecular pathology: a spotlight on the European Masters in Molecular Pathology

通过分子病理学教育实现标准化: 聚焦欧洲分子病理学硕士

2024-10-021
PRE
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
2023-12-153
PRE
SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer
2023-09-042
OAAI
Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer
2022-12-0122
OAAI
DigiPatICS: Digital Pathology Transformation of the Catalan Health Institute Network of 8 Hospitals-Planification, Implementation, and Preliminary Results

Digipathics: 8家医院的加泰罗尼亚卫生研究所网络的数字病理学转型-规划,实施和初步结果

2022-03-3024
OAAI
Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC)
2022-02-150
PRE
Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
2020-11-0211
OAAI
Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study
2020-02-150
PRE
Immune response following neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: A correlative analysis of the SOLTI-1402 CORALLEEN phase 2 randomized trial
2020-02-150
PRE
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer
2019-03-2320
OAAI